|Bid||258.86 x 100|
|Ask||259.67 x 200|
|Day's Range||256.64 - 260.64|
|52 Week Range||208.95 - 279.59|
|PE Ratio (TTM)||68.03|
|Earnings Date||May 8, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||313.33|
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
In this analysis, my focus will be on developing a perspective on BIOTON SA.’s (WSE:BIO) latest ownership structure, a less discussed, but important factor. When it comes to ownership structureRead More...
Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2018 on Tuesday, May 8, 2018, following the close of the market.
When BIOTON SA. (WSE:BIO) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happening inRead More...
We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.
Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.
GNC Holdings' (GNC) tie-up with Rapid Nutrition is likely to fuel the company's entry and expansion into the Australian healthcare market.